News
Sanofi’s Sarclisa combination shows positive results in multiple myeloma patients
The latest results from the phase 3 IKEMA clinical trial evaluating Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone demonstrated an unprecedented median progression free survival (mPFS) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.